PetMed Express, Inc. PETS PHARMA

Q: What is the current share price of PetMed Express, Inc. (PETS)?

As of 2026-09-19 21:16 PDT, PetMed Express, Inc. (PETS) trades at $1.76 on NasdaqGS. Its 52-week range is $1.60 to $3.90.

Q: What is the market capitalisation of PETS?

PetMed Express, Inc. (PETS) has a market capitalisation of $38.15M on NasdaqGS.

Q: What is the P/E ratio of PETS?

PETS trades at a trailing price-to-earnings (P/E) ratio of -1.28. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.48.

Q: What is the return on equity (ROE) of PETS?

PETS has a return on equity (ROE) of -78.56%. Its return on capital employed (ROCE) is -107.74%.

Q: Is PETS a good stock to buy?

This page provides a data-driven analysis of PetMed Express, Inc. (PETS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Pharmaceutical Retailers · United States

https://www.1800petmeds.com

Company Profile ↓

$1.76

-45.17% 1Y

Mkt Cap$38.15M

P/E-1.28

P/B1.48

52W High$3.90

52W Low$1.60

Book Value$1.09

EPS (TTM)$-1.37

Company Overview

PetMed Express, Inc., together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and household pet supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes. The company also sells food, beds, crates, stairs, and other pet supplies. It sells its products through its Internet website; mobile app; customer support center; and direct mail/print, which includes brochures and postcards. The company was incorporated in 1996 and is headquartered in Delray Beach, Florida.

Recent Developments

Trailing 12 Months Year-on-year growth — revenue -19.9%.
5-Year Trend Long-term compounding — revenue CAGR -1.9%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	-1.89%
1 Year:	-19.90%

Stock Price Performance

1 Year:	-45.17%
6 Months:	-32.05%
3 Months:	+3.53%
1 Month:	-11.11%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish

52-Week Range 7% of range

$1.60 $3.90

Trend Signals

Price vs 50-DMABelow
Price vs 200-DMABelow
RSI (14)39.18 · Neutral

Price Performance

1M-11.11%

3M+3.53%

6M-32.05%

1Y-45.17%

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

No notable strengths flagged.

CONS

Revenue declined at -1.9% CAGR over 5 years.
Trading 54.9% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

-1.28

Industry PE

24.83

Forward P/E

-58.67

PEG Ratio

2.32

Book Value

$1.09

Price to Book

1.48

P/S

0.21

EV/EBITDA

-1.14

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

-1.89%

Profit 5Y

Revenue (YoY)

-19.90%

Earnings (YoY)

Profitability & Returns

ROCE

-107.74%

ROE

-78.56%

ROA

-20.05%

Profit Margin

-17.34%

Op Margin

-15.19%

Gross Margin

27.92%

EPS (Latest Qtr)

$-0.19

EPS (TTM)

$-1.37

Balance Sheet & Liquidity

Debt/Equity

1.80

Quick Ratio

0.36

Current Ratio

0.68

Debt

$414.00K

Total Assets

$81.19M

Current Assets

$43.56M

Working Capital

$-8.47M

Ownership

Promoter Holding

16.40%

Chg in Prom Hold

0.83%

FII / Inst Holding

37.66%

Chg in FII Hold

-0.22%

Financial Snapshot

Enterprise Value

$38.15M

Total Revenue (TTM)

$168.86M

EBITDA

$-18.59M

Free Cash Flow

$-15.95M

Operating Cash Flow

$-23.81M

Shares Outstanding

21.68M

Gross Margin

27.92%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	PETS PetMed Express, Inc. PHARMA	1.76	-1.28	$38.15M	0.00%	-107.74%	-78.56%	-1.89%	-
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,123.91	37.80	$1.00T	0.60%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	269.12	31.22	$648.55B	1.98%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	248.78	70.48	$439.62B	2.78%	10.47%	-129.24%	1.75%	-29.06%
5	MRK Merck & Co., Inc. SPXR3KPHARMA	148.46	118.77	$366.28B	2.31%	-	6.96%	5.64%	10.01%
6	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	400.84	25.74	$359.79B	2.47%	9.74%	14.15%	10.40%	5.43%
7	NVS Novartis AG PHARMA	137.70	20.80	$261.73B	3.36%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	160.04	23.99	$248.20B	2.00%	15.97%	21.96%	9.82%	45.96%
9	TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA	603.02	32.49	$222.97B	0.29%	8.14%	13.51%	8.81%	12.95%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Jun 2023	Sep 2023	Dec 2023	Jun 2024	Sep 2024	Dec 2024	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	67.39M	63.16M	57.24M	75.91M	69.46M	63.67M	66.21M	58.04M	51.96M	51.18M	44.36M	40.66M	42.82M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	38.08M	36.78M	31.95M	31.20M	28.88M
Gross Profit	18.91M	16.75M	17.66M	22.45M	18.06M	16.64M	22.16M	27.46M	23.48M	21.94M	24.92M	29.95M	25.25M	19.38M	20.72M	21.86M	20.00M	17.70M	21.69M	26.79M	23.02M	19.62M	20.52M	21.78M	19.17M	17.73M	19.40M	20.89M	20.13M	16.57M	25.00M	21.26M	19.42M	19.04M	18.77M	14.91M	14.40M	12.41M	9.46M	13.94M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	15.36M	21.28M	20.80M	19.93M	19.63M
Operating Income	7.09M	7.62M	8.59M	10.40M	7.73M	7.66M	11.70M	14.42M	12.25M	11.47M	14.00M	15.76M	13.20M	9.41M	7.80M	6.16M	8.37M	7.93M	8.51M	9.44M	10.47M	9.29M	8.39M	5.42M	8.09M	5.15M	7.06M	3.49M	2.96M	-769.00K	-2.13M	875.00K	-3.07M	4.39M	554.00K	-450.00K	-6.87M	-8.38M	-10.47M	-5.69M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.14M	-4.59M	-6.10M	-8.07M	-3.27M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-242.00K	-34.14M	-8.51M	-10.54M	-4.16M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	465.00K	9.00K	9.00K	11.00K	-102.00K
Net Income	4.50M	4.89M	5.42M	6.59M	4.90M	4.82M	7.50M	9.28M	8.76M	9.06M	10.18M	12.58M	10.75M	7.79M	6.62M	5.34M	6.67M	6.84M	7.00M	7.77M	8.41M	7.61M	6.81M	4.43M	6.35M	4.26M	6.07M	2.77M	2.58M	-212.00K	-1.14M	715.00K	-2.03M	3.75M	2.33M	-707.00K	-34.15M	-8.52M	-10.55M	-4.06M
Diluted EPS	0.22	0.24	0.27	0.32	0.24	0.24	0.37	0.45	0.43	0.44	0.50	0.62	0.52	0.38	0.32	0.26	0.33	0.34	0.35	0.39	0.42	0.38	0.34	0.22	0.31	0.21	0.30	0.14	0.13	-0.01	-0.06	0.03	-0.10	0.18	0.11	-0.03	-1.65	-0.41	-0.50	-0.19

Profit & Loss (Annual)

Figures in USD.

Metric	Mar 2010	Mar 2011	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Revenue	238.27M	231.64M	238.25M	227.83M	233.39M	229.40M	234.68M	249.18M	273.80M	283.42M	284.12M	309.21M	272.28M	247.57M	274.10M	-	179.02M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	195.34M	185.84M	202.42M	-	128.81M
Gross Profit	91.86M	83.96M	80.17M	77.12M	77.62M	76.27M	76.30M	79.31M	97.81M	95.31M	81.25M	89.95M	78.08M	71.01M	78.65M	-	50.22M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	52.65M	70.45M	92.93M	-	81.63M
Operating Income	40.54M	33.02M	26.02M	27.00M	28.22M	27.61M	32.39M	37.48M	52.14M	46.17M	30.98M	37.59M	25.71M	-1.43M	-8.16M	-	-31.41M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	27.03M	2.12M	-1.11M	-	-22.03M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	24.18M	1.58M	-6.27M	-	-57.36M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	5.97M	2.31M	1.19M	-	-73.00K
Net Income	26.00M	20.87M	16.66M	17.16M	17.97M	17.45M	20.57M	23.82M	37.28M	37.74M	25.85M	30.60M	21.10M	233.00K	-7.46M	-	-57.29M
Diluted EPS	1.14	0.92	0.80	0.86	0.90	0.87	1.02	1.17	1.82	1.84	1.29	1.52	-	0.01	-0.37	-0.30	-2.74

Balance Sheet (Annual)

Figures in USD.

Metric	Mar 2009	Mar 2010	Mar 2011	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Total Assets	-	-	106.29M	91.06M	73.18M	78.38M	82.85M	90.28M	112.81M	134.84M	154.43M	155.32M	187.50M	179.70M	164.12M	169.88M	148.70M	81.19M
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	151.00M	130.43M	93.65M	-	43.56M
Cash & Equivalents	30.13M	53.14M	49.66M	46.80M	18.16M	18.30M	35.61M	37.64M	58.73M	77.94M	100.53M	103.76M	118.72M	111.08M	104.09M	55.30M	54.72M	21.41M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	32.45M	19.02M	28.56M	-	13.61M
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	1.91M	1.74M	3.28M	-	1.91M
Total Liabilities	-	-	9.28M	9.88M	9.16M	8.16M	7.42M	7.08M	19.44M	19.11M	19.75M	25.31M	46.22M	56.25M	57.51M	73.15M	63.57M	52.25M
Current Liabilities	-	-	8.96M	9.39M	9.00M	8.09M	7.42M	7.08M	18.36M	18.11M	18.63M	24.34M	44.94M	33.20M	36.50M	72.16M	62.77M	52.03M
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	1.45M	-	535.00K
Total Equity	74.97M	96.86M	97.00M	81.18M	64.01M	70.22M	75.44M	83.19M	93.37M	115.73M	134.68M	130.01M	124.93M	142.19M	123.80M	96.73M	85.13M	28.94M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	20.98M	21.08M	21.15M	-	21.39M

Cash Flows (Annual)

Figures in USD.

Metric	Mar 2010	Mar 2011	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow	-	-	-	-	-	-	21.05M	47.20M	37.38M	45.14M	38.84M	40.08M	18.50M	27.80M	4.32M	4.72M	-28.39M
Investing Cash Flow	-	-	-	-	-	-	-4.49M	-10.60M	-703.00K	-620.00K	-2.31M	-2.43M	-1.75M	-10.26M	-40.67M	-5.11M	-4.62M
Financing Cash Flow	-	-	-	-	-	-	-14.54M	-15.51M	-17.47M	-21.93M	-33.30M	-22.69M	-24.38M	-24.54M	-12.44M	-181.00K	-299.00K
Capital Expenditure	-1.05M	-667.00K	-705.00K	-626.00K	-45.00K	-918.00K	-20.13M	-10.60M	-703.00K	-620.00K	-2.31M	-2.43M	-1.75M	-5.26M	-4.51M	-5.11M	-4.62M
Free Cash Flow	-	-	-	-	-	-	923.00K	36.60M	36.68M	44.52M	36.53M	37.64M	16.75M	22.54M	-194.00K	-395.00K	-33.01M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-	-7.64M	-6.99M	-48.79M	-	-33.31M
Share Buybacks	-	12.25M	23.68M	3.87M	-	-	-	-	-	0	11.50M	0	0	-	-	-	-

Ratios (Annual)

Figures in %.

Metric	Mar 2010	Mar 2011	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Gross Margin %	38.6%	36.2%	33.6%	33.9%	33.3%	33.2%	32.5%	31.8%	35.7%	33.6%	28.6%	29.1%	28.7%	28.7%	28.7%	-	28.1%
Operating Margin %	17.0%	14.3%	10.9%	11.9%	12.1%	12.0%	13.8%	15.0%	19.0%	16.3%	10.9%	12.2%	9.4%	-0.6%	-3.0%	-	-17.5%
Net Margin %	10.9%	9.0%	7.0%	7.5%	7.7%	7.6%	8.8%	9.6%	13.6%	13.3%	9.1%	9.9%	7.7%	0.1%	-2.7%	-	-32.0%
ROE %	26.8%	21.5%	20.5%	26.8%	25.6%	23.1%	24.7%	25.5%	32.2%	28.0%	19.9%	24.5%	14.8%	0.2%	-7.7%	-	-197.9%
ROCE %	-	33.9%	31.9%	42.1%	40.1%	36.6%	38.9%	39.7%	44.7%	34.0%	23.7%	26.4%	17.5%	-1.1%	-8.4%	-	-107.7%

Shareholding Pattern

Insiders

16.40%

Institutions

37.66%

Public Float

45.05%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Renaissance Technologies, LLC	5.22%	1.13M	$1.82M
2	Vanguard Capital Management LLC	3.82%	827.40K	$1.33M
3	Blackrock Inc.	2.62%	568.25K	$914.89K
4	Federated Hermes, Inc.	0.98%	212.17K	$341.59K
5	Geode Capital Management, LLC	0.94%	204.07K	$328.56K
6	Steel Partners Holdings, LP	0.89%	193.66K	$311.80K
7	UBS Group AG	0.64%	138.33K	$222.71K
8	Price (T.Rowe) Associates Inc	0.60%	129.93K	$209.19K
9	Bridgeway Capital Management, LLC	0.56%	121.05K	$194.89K
10	Rangeley Capital, LLC	0.56%	121.00K	$194.81K

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for PETS

Google News Mon, 22 Jun 2026

What makes PetMed Express, Inc. (PETS) one of the Best Pet Care Stocks to Buy for Consistent Recurring Revenue? - finance.yahoo.com

<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxPY3daNXlWRU1yOHRjdXFwUkdoZ18wSm9YRF9ZbzN1TnVLUlNtVVVrWXo0SGRqWlB5NFBaLUhPOS1fODV0cUN3ME9ZYkVqSTFKTGZqZlJMUWh0azE4b0oxWl9waGhKQ1l6WmZjWlAwVjJ3Sl95Mm1fWHhRaTEwaXV2bmhRQ2Z3WS1LeHZZc2…

Google News hu, 13 Aug 2026

PetMed Express (PETS) Stock Falls on Q1 2027 Earnings - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxPRXJtRGViLWdmRXh2TXlQMTU3OTk5SzJ1TDdoLVg5S3FVTVRVaFpyUjRpbTJ5OVBfMEpUWk4tdnhKR2V6R21QWGlkSm5iSDRSeXQyV2FvMVlWOXBfQ3kwNllHcElWSjJmSktfdE9uR0NDNk9qR0RYMVVTcEsyN0c1VGxMeUlMZ1p4bjZkYz…

Google News Mon, 10 Aug 2026

7 Best Pet Stocks to Buy in 2026 | Investing - US News Money

<a href="https://news.google.com/rss/articles/CBMia0FVX3lxTE8xRmpfYnNsaXAzZGJDTGhDNE1uT19GUkFfbFVFY0JXZS1BMlVSMDFEVHpja1NUNndDMUNpckRTRTRqSDJoWGxBT1pxZFNQUHhYNkE0eC1idlV6cko5cGlhNWd6R2JDdnVmMG9V?oc=5" target="_blank">7 Best Pet Stocks to Bu…

Google News Sun, 31 May 2026

PETS - Finviz

<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTFBVUzd6eVJtVExTMUo4WDhFb2gxQWhHdTBWX0hvMTQyWk9ZLW1FX0ZCQnJLSXoxdm41ZXlUbi1MUHpGemVaV1E?oc=5" target="_blank">PETS</a>  <font color="#6f6f6f">Finviz</font>…

Google News hu, 13 Aug 2026

PetMeds Acquired 70,000 New Customers in First Quarter - Stock Titan

<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxORWxuSmo2RkM1cHVlX0xaYTNoX3lxT3NRbkJ6Y2RzQWJhVXAxbGYyTEhPX29tOXZiNGwxdWNTN29uNWJ2WDBvVDAxR1ZOZWxvTVRSV0VLN2R4akJEX09NOEJzREFwNHoxclFiY1I1Rm1qc0ZPc0pmVERZaHQyRHVzLTRMQzlna1N5dlMxWG…

Google News Wed, 08 Jul 2026

Pet Stocks Have Slipped Since COVID. Is This an Investing Pup-ortunity? - Kiplinger

<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxNUU0wemszdUtLcWp4Y2NXN3d0cmFkZVp1OW1tY2R2WFNpdENjZGlCWktoUEJmQmNLaDVrYTdNTEZkWTR2dlREUzRIcGZ1cTRkSUFKLVdHTlM4S1RWMldmbW1vZkZkUUZkX2ZHdWJ0WU1MX0RoVWcybEJ5dHVVb2FWdEFYRWxZbWxRYTZQUX…

PETS — Frequently Asked Questions

What is the current share price of PetMed Express, Inc. (PETS)?

As of 2026-09-19 21:16 PDT, PetMed Express, Inc. (PETS) trades at $1.76 on NasdaqGS. Its 52-week range is $1.60 to $3.90.

What is the market capitalisation of PETS?

PetMed Express, Inc. (PETS) has a market capitalisation of $38.15M on NasdaqGS.

What is the P/E ratio of PETS?

PETS trades at a trailing price-to-earnings (P/E) ratio of -1.28. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.48.

What is the return on equity (ROE) of PETS?

PETS has a return on equity (ROE) of -78.56%. Its return on capital employed (ROCE) is -107.74%.

Is PETS a good stock to buy?

This page provides a data-driven analysis of PetMed Express, Inc. (PETS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

PetMed Express, Inc. PETS PHARMA

Company Overview

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

What makes PetMed Express, Inc. (PETS) one of the Best Pet Care Stocks to Buy for Consistent Recurring Revenue? - finance.yahoo.com

PetMed Express (PETS) Stock Falls on Q1 2027 Earnings - Quiver Quantitative

7 Best Pet Stocks to Buy in 2026 | Investing - US News Money

PETS - Finviz

PetMeds Acquired 70,000 New Customers in First Quarter - Stock Titan

Pet Stocks Have Slipped Since COVID. Is This an Investing Pup-ortunity? - Kiplinger

PETS — Frequently Asked Questions

What is the current share price of PetMed Express, Inc. (PETS)?

What is the market capitalisation of PETS?

What is the P/E ratio of PETS?

What is the return on equity (ROE) of PETS?

Is PETS a good stock to buy?

Explore More